Skip to content
    Drishti.money
    Earnings calls

    Dr Reddy's Labs concall ledger

    Every earnings call for DRREDDY — management tone, guidance, KPIs and promise tracking, quarter by quarter.

    DRREDDY · 5 transcripts · Healthcare · latest Q4 FY26
    Q3 FY26Published 21 Jan 2026Call held 28 Oct 2025

    DRREDDY Q3 FY26 Earnings Call Transcript & Analysis

    Operating Revenue₹11,905 cr+29% YoYOperating EBITDA₹1,509 cr+40% YoYEBITDA Margin12.7 percent+100% YoYPAT₹906 cr+37% YoYPBT₹1,226 cr+37% YoY

    Operating Revenue ₹11,905 cr (+29% YoY); Operating EBITDA ₹1,509 cr (+40% YoY); EBITDA Margin 12.7 percent (+100% YoY). Achieved highest ever quarterly sales in both ICE and EV segments with strong outperformance vs industry.

    Read full transcript & analysis
    Q2 FY26Published 24 Oct 2025Call held 24 Oct 2025

    DRREDDY Q2 FY26 Earnings Call Transcript & Analysis

    Consolidated Revenue₹8,805 cr+10% YoYEBITDA₹2,351 cr+3% YoYEBITDA Margin26.7%−174% YoYProfit After Tax₹1,437 cr+14% YoY

    Consolidated Revenue ₹8,805 cr (+10% YoY); EBITDA ₹2,351 cr (+3% YoY); EBITDA Margin 26.7% (−174% YoY). Revenue growth of 9.8% YoY to ₹8,805 crores with near double-digit growth.

    Read full transcript & analysis
    Q4 FY25Published 09 May 2025Call held 09 May 2025

    DRREDDY Q4 FY25 Earnings Call Transcript & Analysis

    Q4 Revenue₹8,506 cr+20% YoYFull Year Revenue₹32,554 cr+17% YoYQ4 EBITDA₹2,475 cr+32% YoYFull Year EBITDA₹9,213 cr+11% YoYQ4 Gross Margin55.6 percentage−3% YoY

    Q4 Revenue ₹8,506 cr (+20% YoY); Full Year Revenue ₹32,554 cr (+17% YoY); Q4 EBITDA ₹2,475 cr (+32% YoY). Record high revenues exceeding $3.8 billion for full year FY25.

    Read full transcript & analysis